GeNeuro is a Swiss biotechnology company focused on developing novel antibody therapies for autoimmune and neurodegenerative diseases. The company targets endogenous retroviral proteins (HERV) that have been implicated in the pathogenesis of certain neurological conditions.
Temelimab (GNK01): Previously developed for MS, showed modulation of HERV-W in Phase 2 trials
Development refocused to ALS based on emerging evidence
Technology Platform
GeNeuro's platform is based on targeting endogenous retroviral elements:
HERV-K: Human endogenous retrovirus K - associated with ALS
HERV-W: Human endogenous retrovirus W - associated with MS, type 1 diabetes
These viral remnants have been implicated in:
Amyotrophic lateral sclerosis (ALS)[@herv_als]
Multiple sclerosis[@herv_ms]
Other autoimmune conditions
Potentially other neurodegenerative diseases
Scientific Rationale
HERV Biology
...
Overview
GeNeuro is a Swiss biotechnology company focused on developing novel antibody therapies for autoimmune and neurodegenerative diseases. The company targets endogenous retroviral proteins (HERV) that have been implicated in the pathogenesis of certain neurological conditions.
Temelimab (GNK01): Previously developed for MS, showed modulation of HERV-W in Phase 2 trials
Development refocused to ALS based on emerging evidence
Technology Platform
GeNeuro's platform is based on targeting endogenous retroviral elements:
HERV-K: Human endogenous retrovirus K - associated with ALS
HERV-W: Human endogenous retrovirus W - associated with MS, type 1 diabetes
These viral remnants have been implicated in:
Amyotrophic lateral sclerosis (ALS)[@herv_als]
Multiple sclerosis[@herv_ms]
Other autoimmune conditions
Potentially other neurodegenerative diseases
Scientific Rationale
HERV Biology
Endogenous retroviruses are remnants of ancient viral infections integrated into the human genome. In certain conditions, these dormant viral sequences can become active and produce proteins that may trigger immune responses or directly contribute to disease pathology.
HERV-K in ALS
Research has demonstrated elevated HERV-K expression in ALS patients[@herv_als]:
Viral protein expression: HERV-K env protein detected in motor neurons of ALS patients
Neurotoxicity: HERV-K envelope protein is directly toxic to motor neurons[@herv_pseudo]
Immune activation: HERV-K triggers inflammatory responses in microglia
Genetic association: HERV-K polymorphisms linked to ALS risk
HERV-W in MS
HERV-W was originally identified as the MS-associated retrovirus (MSRV):
Envelope protein: MSRV env shows pro-inflammatory and neurotoxic properties
Therapeutic target: Antibodies against HERV-W (temelimab) tested in MS trials
Mechanism: Binds to TLR4 on immune cells, triggering NF-κB activation
Comparison with Other Neurodegeneration Companies
| Company | Approach | Disease Focus | Stage | |---------|----------|--------------|-------| | GeNeuro | HERV antibodies | ALS, MS | Preclinical | | AC Immune | Tau/α-syn antibodies | AD, PD | Phase 2-3 | | Biogen | Anti-sense oligonucleotides | ALS, AD | Various | | Ionis | RNA targeting | Multiple | Various |
Market Opportunity
ALS Market
Global ALS market: ~$1B annually, growing
Unmet need: No disease-modifying therapies approved
HERV target: Addresses novel pathway not targeted by other approaches